GO:0035768 endothelial cell chemotaxis to fibroblast growth factor: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035768 describes the directed movement of endothelial cells toward fibroblast growth factor (FGF) gradients, a key process in angiogenesis and tissue repair.
• FGF signaling, particularly bFGF/FGF-2, interacts with heparan sulfate proteoglycans on endothelial cells to promote migration and neovascularization.
• Endothelial chemotaxis to FGF is critical in pathological conditions such as inflammatory arthritis, diabetic wound healing, and tumor angiogenesis.
• The process involves coordinated activation of PI3K, calcium signaling, and adhesion molecule expression.
• Key genes include FGF2, FGFR1, and downstream effectors such as PI3K and adhesion molecules.
• CRISPR-based models (knockout, knock-in, overexpression) enable precise dissection of FGF-driven endothelial chemotaxis in vitro and in vivo.
Description
Endothelial cell chemotaxis to fibroblast growth factor (GO:0035768) is a biological process defined as the directed movement of an endothelial cell in response to the presence of fibroblast growth factor (FGF). This process is fundamental to angiogenesis, the formation of new blood vessels from existing ones, and is essential for embryonic development, wound healing, and tissue regeneration. FGF family members, particularly basic FGF (bFGF/FGF-2), act as potent chemoattractants for endothelial cells, guiding them toward sites of injury or hypoxia. The interaction of FGF with endothelial cell surface heparan sulfate proteoglycans is a critical first step that modulates FGF bioavailability and signaling specificity. Dysregulation of this chemotactic response contributes to numerous pathologies, including chronic inflammatory diseases, diabetic ulcers, and cancer progression. Understanding the molecular players and regulatory mechanisms of GO:0035768 is therefore of significant biomedical interest. This article synthesizes authoritative QuickGO annotations and verified PubMed literature to provide a comprehensive overview of the genes, functions, and research methods associated with this term.
endothelial cell chemotaxis to fibroblast growth factor At A Glance
| GO ID | GO:0035768 |
|---|---|
| GO term | endothelial cell chemotaxis to fibroblast growth factor |
| Ontology | biological_process |
| Synonym | None |
| Definition | The directed movement of an endothelial cell in response to the presence of fibroblast growth factor (FGF). |
| Major function | Guides endothelial cell migration during angiogenesis and tissue repair. |
| Related processes | Angiogenesis, wound healing, inflammation, neovascularization. |
| Key ligands | FGF family members, particularly FGF-2 (bFGF). |
| Key receptors | FGFR1, FGFR2, and heparan sulfate proteoglycans. |
What Is GO:0035768?
GO:0035768, endothelial cell chemotaxis to fibroblast growth factor, is defined by the Gene Ontology as the directed movement of an endothelial cell in response to the presence of fibroblast growth factor (FGF). In simpler terms, it is the process by which endothelial cells sense a gradient of FGF and migrate toward higher concentrations of this growth factor. This chemotactic behavior is distinct from random migration and requires specific receptor-ligand interactions, intracellular signaling cascades, and cytoskeletal rearrangements that ultimately drive directional cell motility.
Why Is endothelial cell chemotaxis to fibroblast growth factor Important in Cell Biology?
Endothelial cell chemotaxis to FGF is a cornerstone of vascular biology and is indispensable for both physiological and pathological angiogenesis. It ensures that new blood vessels form in the right place at the right time, supplying oxygen and nutrients to growing tissues. In wound healing, FGF released by damaged cells and inflammatory cells attracts endothelial cells to rebuild the vasculature. In cancer, tumor-secreted FGF drives endothelial chemotaxis to support tumor angiogenesis, a hallmark of cancer progression. In chronic inflammatory diseases such as rheumatoid arthritis, FGF-mediated endothelial migration contributes to synovial neovascularization and disease persistence. Thus, understanding GO:0035768 offers opportunities for therapeutic intervention in diverse conditions.
• Essential for angiogenesis during embryonic development and tissue repair.
• Drives neovascularization in diabetic foot ulcers, where impaired FGF signaling contributes to poor healing.
• Promotes endothelial cell recruitment in inflammatory arthritis, exacerbating synovial inflammation.
• Supports tumor angiogenesis, facilitating cancer growth and metastasis.
• Involves crosstalk with other growth factors and cytokines, such as hepatocyte growth factor (HGF).
• Requires heparan sulfate proteoglycans for optimal FGF presentation and signaling.
• Modulated by intracellular calcium and phosphatidylinositol 3-kinase (PI3K) pathways.
• Can be potentiated by inflammatory mediators that upregulate endothelial adhesion molecules.
• Represents a target for anti-angiogenic therapies in oncology and ophthalmology.
• Provides a model system to study directed cell migration and signal transduction.
What Happens During endothelial cell chemotaxis to fibroblast growth factor?
FGF Presentation and Receptor Binding
In simple terms: FGF sticks to the cell surface and binds its receptor, starting the migration signal.
The process begins when fibroblast growth factors (FGFs), such as bFGF/FGF-2, are released into the extracellular environment. These growth factors bind to heparan sulfate proteoglycans on the endothelial cell surface, which act as co-receptors and facilitate the formation of FGF-FGFR-heparan sulfate ternary complexes. This interaction stabilizes FGF and enhances its binding to high-affinity tyrosine kinase receptors (FGFRs) on the endothelial cell membrane. Receptor dimerization and autophosphorylation then trigger intracellular signaling cascades.
Intracellular Signaling and Cytoskeletal Rearrangement
In simple terms: Signals inside the cell tell the skeleton to move the cell forward.
Activated FGFRs phosphorylate downstream targets, leading to the activation of phosphatidylinositol 3-kinase (PI3K) and the production of phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PI3K signaling is essential for endothelial cell interactions with collagen matrices and for chemotaxis in vitro and in vivo. Additionally, free cytoplasmic calcium serves as a critical second messenger, regulating actin cytoskeleton dynamics and focal adhesion turnover. These events polarize the cell, with actin polymerization at the leading edge and actomyosin contraction at the rear, driving directional movement toward the FGF source.
Adhesion Molecule Modulation and Leukocyte Crosstalk
In simple terms: FGF also makes the endothelium sticky for immune cells, linking migration to inflammation.
Beyond direct chemotaxis, FGF-2 potentiates leukocyte recruitment by enhancing the expression of endothelial adhesion molecules such as ICAM-1 and VCAM-1. This crosstalk amplifies the inflammatory response and may indirectly influence endothelial migration by creating a pro-angiogenic microenvironment. In conditions like inflammatory arthritis, hepatocyte growth factor (HGF) acts as another cytokine mediating endothelial migration, often in concert with FGF. Thus, FGF-driven chemotaxis is integrated with broader inflammatory and angiogenic networks.
Resolution and Vessel Stabilization
In simple terms: Once the cells arrive, they form new blood vessels and stop migrating.
After endothelial cells reach the FGF-rich site, they proliferate and organize into tube-like structures, a process that requires the downregulation of chemotactic signaling and the upregulation of stabilization factors. While the exact resolution mechanisms for GO:0035768 are not fully defined in the cited literature, it is clear that persistent FGF signaling can lead to excessive angiogenesis, as seen in tumors and chronic inflammatory diseases. The transition from migration to stabilization involves interactions with pericytes and extracellular matrix components, though further research is needed to fully elucidate these steps.
Key Genes Involved in GO:0035768 endothelial cell chemotaxis to fibroblast growth factor
The following genes and proteins are central to endothelial cell chemotaxis to fibroblast growth factor, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FGF2 | Primary chemoattractant ligand (bFGF) that binds FGFRs and heparan sulfate proteoglycans. | Knockout or overexpression models to study angiogenesis and wound healing. |
| FGFR1 | High-affinity receptor tyrosine kinase that mediates FGF signaling. | Point mutations to dissect signaling pathways; knockout to block chemotaxis. |
| FGFR2 | Receptor tyrosine kinase that also binds FGFs and contributes to endothelial migration. | Knockdown or knockout to assess redundancy with FGFR1. |
| HSPG2 | Heparan sulfate proteoglycan (perlecan) that presents FGF to its receptor. | Knockout to impair FGF bioavailability and chemotaxis. |
| PIK3CA | Catalytic subunit of PI3K, essential for FGF-induced chemotaxis. | Knockout or point mutation to block PI3K signaling. |
| PIK3CB | Regulatory subunit of PI3K, modulates signaling specificity. | Knock-in of mutant alleles to study isoform-specific effects. |
| ICAM1 | Adhesion molecule upregulated by FGF-2, facilitating leukocyte-endothelial interactions. | Overexpression or knockout to study inflammation-angiogenesis crosstalk. |
| VCAM1 | Adhesion molecule induced by FGF-2, involved in leukocyte recruitment. | Knockout models to assess contribution to FGF-mediated inflammation. |
| HGF | Hepatocyte growth factor, a cytokine that mediates endothelial migration in arthritis. | Overexpression or knockout in arthritis models. |
| MET | Receptor for HGF, activates pro-migratory signaling. | Point mutations to study HGF-driven chemotaxis. |
| CALM1 | Calmodulin, mediates calcium-dependent signaling in chemotaxis. | Knockout or knockdown to disrupt calcium signaling. |
| ACTB | Beta-actin, major cytoskeletal component for cell motility. | Tagged knock-in for live imaging of actin dynamics. |
| RAC1 | Rho GTPase, regulates actin polymerization at the leading edge. | Knockout or point mutation to block directional migration. |
| CDC42 | Rho GTPase, controls filopodia formation and cell polarity. | Knockout to study loss of directionality. |
| VEGFA | Vascular endothelial growth factor, synergizes with FGF in angiogenesis. | Overexpression or knockout to study cooperative chemotaxis. |
| MMP2 | Matrix metalloproteinase, degrades extracellular matrix to allow migration. | Knockout to assess matrix remodeling during chemotaxis. |
| MMP9 | Matrix metalloproteinase, facilitates endothelial cell invasion. | Knockout or inhibitor studies. |
| S100A4 | S100 protein, involved in cell motility and angiogenesis. | Knockout or overexpression to study calcium-binding protein function. |
How Is endothelial cell chemotaxis to fibroblast growth factor Regulated?
The process of endothelial cell chemotaxis to FGF is tightly regulated at multiple levels. Extracellularly, heparan sulfate proteoglycans modulate FGF bioavailability and receptor binding, acting as co-receptors that enhance or inhibit signaling. Intracellularly, PI3K signaling is a key node; its activation is required for endothelial cell interactions with collagen matrices and for chemotaxis in vitro and in vivo. Free cytoplasmic calcium also plays a regulatory role, influencing cytoskeletal dynamics and focal adhesion turnover. In inflammatory contexts, FGF-2 potentiates leukocyte recruitment by upregulating adhesion molecules, which can indirectly amplify chemotactic responses. Additionally, other cytokines such as hepatocyte growth factor (HGF) can synergize with or independently mediate endothelial migration, highlighting the complexity of regulatory networks. While specific transcription factors or microRNAs regulating GO:0035768 are not detailed in the cited literature, the interplay between FGF, PI3K, calcium, and adhesion molecules provides a framework for understanding its control.
endothelial cell chemotaxis to fibroblast growth factor and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FGF2 | Diabetic foot ulcers, cancer, inflammatory arthritis | Knockout mice, overexpression in endothelial cells, wound healing assays. |
| FGFR1 | Cancer, angiogenesis disorders | Point mutation knock-in mice, endothelial-specific knockout. |
| HGF | Inflammatory arthritis | HGF transgenic mice, knockout in arthritis models. |
| PIK3CA | Angiogenesis defects, cancer | Endothelial-specific knockout, point mutation knock-in. |
| ICAM1 | Inflammation, cancer | Overexpression or knockout in endothelial cells. |
Diabetic Foot Ulcers and Impaired Wound Healing
Diabetic foot ulcers are characterized by impaired wound healing, often due to defective angiogenesis. Integrated skin transcriptomics and serum multiplex assays have revealed novel mechanisms of wound healing in diabetic foot ulcers, including alterations in FGF signaling and endothelial cell chemotaxis. Reduced FGF-mediated endothelial migration may contribute to poor vascularization and delayed healing. Understanding GO:0035768 in this context could inform therapies to restore chemotaxis and promote tissue repair.
Inflammatory Arthritis
In inflammatory arthritis, such as rheumatoid arthritis, hepatocyte growth factor (HGF) acts as a cytokine mediating endothelial migration, contributing to synovial neovascularization and inflammation. FGF also plays a role in this process, and the interplay between HGF and FGF may exacerbate disease. Targeting endothelial chemotaxis to FGF could reduce pathological angiogenesis in arthritic joints.
Cancer and Tumor Angiogenesis
Tumor cells often secrete FGF to stimulate endothelial cell chemotaxis, promoting angiogenesis that supports tumor growth and metastasis. Basic FGF interacts with heparan sulfate proteoglycans on endothelial cells to drive neovascularization. Inhibiting this chemotactic process is a strategy for anti-angiogenic cancer therapy. Additionally, FGF-2 potentiates leukocyte recruitment by enhancing endothelial adhesion molecule expression, which may contribute to the inflammatory tumor microenvironment.
Fibrosis and Tissue Remodeling
Fibrosis involves excessive deposition of extracellular matrix and is often accompanied by aberrant angiogenesis. Cellular and molecular mechanisms of fibrosis highlight the role of growth factors, including FGF, in driving endothelial cell migration and vascular remodeling. Matrix metalloproteinases such as MMP2 and MMP9 facilitate endothelial invasion during fibrosis. Modulating FGF-driven chemotaxis may offer therapeutic avenues for fibrotic diseases.
From endothelial cell chemotaxis to fibroblast growth factor-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does FGF2 drive endothelial chemotaxis in vivo? | Endothelial-specific FGF2 knockout or overexpression mouse models. |
| What is the role of FGFR1 kinase activity in chemotaxis? | Point mutation (kinase-dead) knock-in of FGFR1 in endothelial cells. |
| How does PI3K signaling contribute to FGF-induced migration? | Endothelial-specific PIK3CA knockout or knock-in of constitutively active PI3K. |
| Can heparan sulfate proteoglycans modulate FGF chemotaxis? | HSPG2 knockout or knockdown in endothelial cells. |
| Does FGF-2 potentiate leukocyte recruitment via adhesion molecules? | ICAM1/VCAM1 knockout or overexpression in endothelial cells. |
| What is the role of calcium signaling in FGF chemotaxis? | CALM1 knockout or tagged knock-in for live calcium imaging. |
How to Study the endothelial cell chemotaxis to fibroblast growth factor Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Boyden chamber assay | Directional migration toward FGF | Screening for chemotaxis inhibitors or gene knockouts. |
| Microfluidic gradient device | Real-time chemotaxis under defined gradients | Live imaging of cytoskeletal dynamics. |
| RNA-seq | Transcriptional changes during chemotaxis | Identifying novel regulators in diabetic ulcers. |
| Proteomics | Protein expression and phosphorylation | Mapping signaling pathways downstream of FGFR. |
| Live-cell imaging | Actin dynamics and cell polarity | Visualizing migration in real time. |
| Immunohistochemistry | Endothelial cell localization in tissues | Assessing angiogenesis in arthritis or tumors. |
| Serum multiplex assay | Cytokine levels (FGF, HGF) | Correlating systemic factors with wound healing. |
| CRISPR screening | Genome-wide identification of regulators | Discovering novel genes required for chemotaxis. |
In Vitro Chemotaxis Assays
The Boyden chamber and microfluidic gradient devices are standard methods to measure endothelial cell chemotaxis toward FGF. These assays allow precise control of FGF gradients and quantification of directional migration. They can be combined with pharmacological inhibitors or genetic manipulations to dissect signaling pathways.
Live-Cell Imaging and Cytoskeletal Dynamics
Live-cell imaging of fluorescently tagged actin (e.g., ACTB-GFP) or focal adhesion proteins enables real-time visualization of cytoskeletal rearrangements during chemotaxis. This approach reveals polarization, protrusion, and retraction dynamics in response to FGF gradients.
Transcriptomics and Proteomics
RNA-seq and proteomics can identify genes and proteins differentially expressed during FGF-induced endothelial chemotaxis. For example, integrated skin transcriptomics has revealed novel mechanisms of wound healing in diabetic foot ulcers, including FGF-related pathways. Serum multiplex assays can quantify secreted factors like FGF and HGF.
Genetic Manipulation in Animal Models
Mouse models with endothelial-specific knockout or knock-in of FGF pathway genes are invaluable for studying GO:0035768 in vivo. Techniques such as Cre-lox recombination allow spatial and temporal control. These models can be used in wound healing, arthritis, and tumor angiogenesis studies.
How CRISPR Can Be Used to Study GO:0035768 endothelial cell chemotaxis to fibroblast growth factor
Knockout
CRISPR knockout of genes such as FGF2, FGFR1, or PIK3CA in endothelial cells can abolish chemotaxis to FGF, providing causal evidence for their roles. Pooled knockout screens can identify novel regulators of this process. Endothelial-specific knockout mice are useful for in vivo validation.
Point Mutation
Point mutations can be introduced to dissect specific signaling domains. For example, kinase-dead FGFR1 knock-in can distinguish between kinase-dependent and independent functions in chemotaxis. Similarly, mutations in PI3K subunits can reveal isoform-specific contributions.
Knock-in
Knock-in of reporter genes (e.g., GFP-tagged ACTB) allows live imaging of cytoskeletal dynamics during chemotaxis. Knock-in of constitutively active or dominant-negative alleles can modulate pathway activity. Tagged knock-in of FGF2 can track its secretion and presentation.
Overexpression
Overexpression of FGF2 or FGFR1 in endothelial cells can enhance chemotaxis and angiogenesis. Overexpression of adhesion molecules like ICAM1 can potentiate leukocyte recruitment, linking chemotaxis to inflammation. These models are useful for gain-of-function studies.
How EDITGENE Supports endothelial cell chemotaxis to fibroblast growth factor Research
Researchers studying endothelial cell chemotaxis to fibroblast growth factor-related genes often need to determine whether a candidate gene is causally involved in this process or merely correlated with it. CRISPR-based genome editing provides the gold standard for establishing causality by enabling precise genetic perturbations in endothelial cells and animal models.
Contact EDITGENE today to design your custom CRISPR model for endothelial cell chemotaxis to fibroblast growth factor research.
Frequently Asked Questions About endothelial cell chemotaxis to fibroblast growth factor
What is endothelial cell chemotaxis to fibroblast growth factor?
It is the directed movement of endothelial cells toward a source of fibroblast growth factor (FGF), a process essential for angiogenesis and tissue repair.
What genes are involved in endothelial cell chemotaxis to fibroblast growth factor?
Key genes include FGF2, FGFR1, FGFR2, PIK3CA, HSPG2, ICAM1, VCAM1, and HGF, among others.
How is FGF signaling regulated in endothelial chemotaxis?
FGF signaling is regulated by heparan sulfate proteoglycans, PI3K, calcium signaling, and crosstalk with other cytokines like HGF.
What diseases involve endothelial cell chemotaxis to FGF?
Diabetic foot ulcers, inflammatory arthritis, cancer, and fibrosis all involve dysregulated FGF-driven endothelial chemotaxis.
What methods are used to study endothelial cell chemotaxis to FGF?
Common methods include Boyden chamber assays, microfluidic gradients, live-cell imaging, RNA-seq, proteomics, and CRISPR screens.
Can CRISPR be used to study endothelial cell chemotaxis to FGF?
Yes, CRISPR knockout, knock-in, point mutation, and overexpression models enable precise dissection of gene function in this process.
What is the role of heparan sulfate proteoglycans in FGF chemotaxis?
They act as co-receptors that present FGF to its receptor, enhancing signaling and chemotaxis.
How does PI3K contribute to FGF-induced endothelial migration?
PI3K activation is required for endothelial cell interactions with collagen matrices and for chemotaxis in vitro and in vivo.
Is FGF-2 the same as basic FGF?
Yes, FGF-2 is also known as basic fibroblast growth factor (bFGF).
What is the clinical relevance of endothelial cell chemotaxis to FGF?
It is a target for anti-angiogenic therapies in cancer and for promoting wound healing in diabetic ulcers.
Conclusion
Endothelial cell chemotaxis to fibroblast growth factor (GO:0035768) is a fundamental biological process that drives angiogenesis in development, wound healing, and disease. The interplay between FGF ligands, heparan sulfate proteoglycans, receptor tyrosine kinases, and downstream effectors like PI3K and calcium signaling orchestrates directed endothelial cell migration. Dysregulation of this process contributes to diabetic ulcers, inflammatory arthritis, cancer, and fibrosis. CRISPR-based models offer powerful tools to dissect the genetic basis of this chemotaxis and to identify therapeutic targets. Continued research into GO:0035768 will advance our understanding of vascular biology and provide new avenues for treating angiogenesis-related disorders.
References
- 1. Wynn TA. 2008. Cellular and molecular mechanisms of fibrosis.. J Pathol 214(2):199-210 PMID: 18161745
- 2. Donato R et al.. 2013. Functions of S100 proteins.. Curr Mol Med 13(1):24-57 PMID: 22834835
- 3. Theocharidis G et al.. 2020. Integrated Skin Transcriptomics and Serum Multiplex Assays Reveal Novel Mechanisms of Wound Healing in Diabetic Foot Ulcers.. Diabetes 69(10):2157-2169 PMID: 32763913
- 4. Ahlén K et al.. 1998. Cell interactions with collagen matrices in vivo and in vitro depend on phosphatidylinositol 3-kinase and free cytoplasmic calcium.. Cell Adhes Commun 5(6):461-73 PMID: 9791727
- 5. Rusnati M et al.. 1996. Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization.. Int J Clin Lab Res 26(1):15-23 PMID: 8739851
- 6. Koch AE et al.. 1996. Hepatocyte growth factor. A cytokine mediating endothelial migration in inflammatory arthritis.. Arthritis Rheum 39(9):1566-75 PMID: 8814069
- 7. Joseph-Silverstein J et al.. 1987. Endothelial cell growth factors and the vessel wall.. Semin Thromb Hemost 13(4):504-13 PMID: 3321439
- 8. Zittermann SI et al.. 2006. Basic fibroblast growth factor (bFGF, FGF-2) potentiates leukocyte recruitment to inflammation by enhancing endothelial adhesion molecule expression.. Am J Pathol 168(3):835-46 PMID: 16507899
